Stem Cell Source Global Market Report 2020 2025: Post Covid 19 Impact and Recovery – The Think Curiouser

The recent research report titled(COVID-19 Version) Global Stem Cell Source Market Status (2015-2019) and Forecast (2020-2025) by Region, Product Type & End-Usehas been added in thekandjmarketresearch.comdatabase. This market report is a valuable source of insightful data for business strategists. It offers the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types, and end industries. ThisGlobal Stem Cell Source Marketstudy provides comprehensive data that enhances the understanding, scope, and application of this report.

Market Overview Indispensable insights of theStem Cell Source marketare elaborated in the report. The core objective of the report is to deliver reliable and concrete information about the Stem Cell Source market that can assist the businessmen to make rational decisions. The expected CAGR and valuation of the Stem Cell Source market are mentioned in the report. Proficient analysts have studied the market for the evaluation year of 2020 to 2025. Significant factors that are likely to promote the growth of the Stem Cell Source market and possible constraints of the market are elaborated in this market research report. Potential growth scopes are also elaborated in the report. The Global Stem Cell Source Market studied in segments to provide information about the same market that encompasses crucial aspects of the Stem Cell Source industry or market. The regional progress of the Stem Cell Source market is studied under the regional outlook section. A lucid understanding of the transforming competitive landscape of the market can assist investors in several ways. North America, Europe, and APAC are key regions across which is in the studied. For the Rest of the World (RoW), the Stem Cell Source market is analyzed across Latin America, South America, and the Middle East Asia and Africa.

The Final Report Will Include the Post Impact of COVID 19 Analysis in This Industry.For Sample Report & Graphs & Charts @:www.kandjmarketresearch.com/sample-request/506577

The latest report includes Post Impact of Coronavirus(Covid-19) on the Stem Cell Source Industry, it includes on Industry Upstream, Industry Downstream, Industry Channels, Industry Competition, and finally on Industry Employment.

Key Benefits 1. Comprehensive analysis of the current trends and future estimations in the global Stem Cell Source market. 2. The report offers a competitive scenario of the market and elucidates the growth trends, drivers, scope, opportunities, and challenges. 3. It also includes a comprehensive analysis of the key segments to provide insights on the market dynamics. 4. Porters Five Forces analysis highlights the potential of buyers and suppliers to devise effective growth strategies and facilitate better decision-making. 5. Market player provides positions of key companies operating in the market.

Key Players overview Credible sources, such as surveys, financial magazines, and whitepapers are referred for listing key players of the Stem Cell Source market. However, interviews with well-known personalities, such as CEOs, COO, and entrepreneurs are accepted as the most effective tool to prepare contribution of key players towards the growth of the Stem Cell Source market. Past aspects and current trends of market players are elaborated in the report. The financial status of market players and their contributions are discussed in the report that offers a clear understanding to the investors and aids them in making rational decisions.

Key Companies: BD Bioscience, Beckman Coulter, Ge Healthcare, Merck Millipore, Miltenyi Biotec, Pluriselect Life Science, Sigma-Aldrich Corporation, Stemcell Technologies, Terumo BCT, Thermo Fisher ScientificCompany 13

Ask for Discount @www.kandjmarketresearch.com/discount/506577

Key Types: Reagent, Instrument, Others

Key End-Use / Application: Hospital, Biotechnology Research Center, Others

Research Methodology Research methodologies utilized in cooking the report are rigorous and fail-safe. The robust scoring process is employed to deliver an objective and accurate overview of the Global Stem Cell Source Market. Modern research techniques used to offer vivid qualitative and qualitative findings of the Stem Cell Source industry. The Stem Cell Source research techniques used to study the Global Stem Cell Source Market aid in the collection of evidence and data to deliver precise report. The market research firm uses various tools for the collection of information for primary and secondary analysis of the Stem Cell Source market to prepare a report that can be an ultimate guide for investors. Top-down and bottom-up approaches maintained for the assessment of the Stem Cell Source market for the forecast years ensures high-quality and valuable insights into the Stem Cell Source market. Read More Detailed Information regardingStem Cell Source Industry with Post Covid-19 Updates @www.kandjmarketresearch.com/reports/506577

About Us : Kandjmarketresearch.com is part of the KnowledgeNJournals Research Firm which provides premium progressive market research reports, statistical surveying, analysis & forecast data for industries and governments from hundreds of publishers around the world. We have almost all top publishers reports in our collection to provide you with instant online access to the worlds most complete and fresh database on a Daily Basis. We are at KandJ Market Research are inspired to help our clients grow by providing appropriate business insight with our huge market intelligence source. If you have any special requirements for the report, please let us know and we will offer you a customized report on separate regional or country-level reports.

Contact us:- Yash KandJ Market Research(Part of KnowledgeNJournals Research) USA:+1 (661) 636 6162 |IND:+91 9325802062 Email:[emailprotected];Web:www.kandjmarketresearch.com

Here is the original post:
Stem Cell Source Global Market Report 2020 2025: Post Covid 19 Impact and Recovery - The Think Curiouser

Prop. 14: In the COVID age, can California still afford its stem cell research program? – CALmatters

In summary

Proposition 14 asks voters to spend nearly $8 billion to continue the stem cell research program at a time when the coronavirus pandemic has decimated the state budget.

For the second time in 16 years, California voters will decide the fate of the states multi-billion dollar stem cell research program that established the state as a worldwide leader.

How the times have changed.

In November, as the pandemic drags on, Proposition 14 asks voters to spend nearly $8 billion to continue the program during a period when the research environment has significantly evolved and coronavirus has battered the states budget.

The bond measure would approve $5.5 billion in bonds to keep the states stem cell research agency running and grants flowing to California universities and companies.

At least $1.5 billion would be earmarked for brain and central nervous system diseases like Alzheimers and Parkinsons. The overall cost of the bonds and their interest totals about $7.8 billion, according to the state legislative analyst. The state would pay about $260 million annually for 30 years, or about 1 percent of Californias annual budget.

Proposition 14 is essentially a repeat with a bigger price tag and a few tweaks of Proposition 71, which California voters approved in 2004 after then-President George W. Bush prohibited, on religious grounds, all federal funding of any stem cell research using human embryos.

The bond measure would approve $5.5 billion in bonds to keep the states stem cell research agency running and grants flowing to California universities and companies.

That groundbreaking measure authorized $3 billion in state bonds to create the states stem cell research agency, the California Institute for Regenerative Medicine, and fund grants for research into treatments for Alzheimers disease, cancer, spinal cord injuries and other diseases.

The institute has nearly used up its original funding, so Prop. 71s author, real estate investor and attorney Robert N. Klein II, led a new effort to get Prop. 14 on the November ballot.

This time, embryonic stem cell research is in a much different place, with federal funding no longer blocked and more funding from the biotech industry.

Voters will want to consider what Californias previous investment in stem cell research has accomplished. Its a nuanced track record.

While many scientific experts agree that Prop 71 was a bold social innovation that successfully bolstered emerging stem cell research, some critics argue that the institutes grantmaking was plagued by conflicts of interest and did not live up to the promises of miracle cures that Prop. 71s supporters made years ago. Although the agency is funded with state money, its overseen by its own board and not by the California governor or lawmakers.

The agency had done a very good job of setting priorities for stem cell research, including research using human embryos, and doling out $300 million annually to build up California as a regenerative medicine powerhouse, according to a 2013 evaluation by the National Academies of Science, Engineering and Medicine.

But the report also found that because the institutes board is made up of scientists from universities and biotech firms likely to apply for grants, board members had almost unavoidable conflicts of interest.

Keep tabs on the latest California policy and politics news

Because human stem cells can develop into many types of cells, including blood, brain, nerve and muscle cells, scientists have long looked to them for potential treatments for currently incurable diseases and injuries. Researchers use two types of stem cells: embryonic stem cells, derived from unused human embryos created through in vitro fertilization, and adult stem cells, which are harder to work with but in some cases can be coaxed in a lab into behaving more like embryonic stem cells.

From the start, stem cell research has been ethically charged and politically controversial because human embryos are destroyed in some types of studies. Federal restrictions on the research have waxed and waned, depending on which political party holds power. While former President Bush restricted federal money for embryonic stem cell research, former President Obama removed those restrictions.

The Trump administration has restricted government research involving fetal tissue but not embryonic stem cells. However, anti-abortion lawmakers have called on the President to once again end federal funding for embryonic stem cell research.

California-funded research has led to one stem cell treatment for a form of Severe Combined Immunodeficiency known as the bubble baby disease. Children with the rare disease dont make enough of a key enzyme needed for a normal immune system. Without treatment, they can die from the disease if not kept in a protective environment. The U.S. Food and Drug Administration is now reviewing the treatment but has not yet approved it for widespread use.

Although many of the agencys early grants were for basic science, the institute also has supported 64 clinical trials of treatments for many types of cancer, sickle cell disease, spinal cord injuries, diabetes, kidney disease and amyotrophic lateral sclerosis, commonlyknown as Lou Gehrigs disease.

A June 2020 analysis by University of Southern California health policy researchers estimated that taxpayers initial $3 billion investment in the research institute helped create more than 50,000 jobs and generated $10 billion for the states economy.

Gov. Gavin Newsom has endorsed Proposition 14, and other supporters include the Regents of the University of California, the California Democratic Party, the Juvenile Diabetes Research Foundation, patient advocacy groups like the March of Dimes, and some local politicians and chambers of commerce.

Supporters have raised more than $8.5 million, including about $2 million from billionaire Dagmar Dolby, to pass the measure, according to California Secretary of State campaign finance reports.

The passage of Proposition 71 helped save my life, Sandra Dillon, a blood cancer patient, wrote in a San Diego Union-Tribune commentary supporting Proposition 14. She wrote that she had benefited from a drug developed with Institute-funded research that has been designated by the FDA as a breakthrough therapy.

It is unimaginable to think that Californians would vote to discontinue this amazing effort I dont know where I would be or what condition I would be in if it wasnt for the investment Californians made nearly two decades ago.

I think the agencys done good work, but this was never planned to be funded forever with debt.

Lawrence Goldstein, a UC San Diego professor of cellular and molecular medicine and stem cell researcher, said the grants were instrumental in furthering his research on treatments for Alzheimers disease and that Prop. 14 will help create new jobs. The agency has funded a great deal of very important stem cell medical research thats already produced terrific results and has the prospect of saving many more lives in the decade to come, he said.

Opponents include one member of the institutes board and a nonprofit that advocates for privacy in genetic research. They contend that the proposition seeks too much money and does not sufficiently address the conflicts of interest that cropped up after Prop. 71 was passed. They also note that private funding, including venture capital, for stem cell research has grown in recent years. Opponents had raised only $250 by late September, from a single contribution by the California Pro Life Council.

The editorial boards of some of Californias biggest newspapers also have opposed the measure, including the Los Angeles Times, the Orange County Register, the San Francisco Chronicle and the San Jose Mercury News/East Bay Times. The Fresno Bee, Modesto Bee, and San Luis Obispo Tribune newspaper editorial boards support Prop 14.

Jeff Sheehy, the only institute board member not to support Proposition 14, told CalMatters that the research environment has changed since voters initially approved state funding for stem cell research in 2004 and that California should prioritize other needs like education, health care, and housing.

I think the agencys done good work, but this was never planned to be funded forever with debt, Sheehy said. At this point the state cant afford it; were looking at a huge deficit.

As a nonprofit newsroom, we rely on the generosity of Californians like you to cover the issues that matter. If you value our reporting, support our journalism with a donation.

Follow this link:
Prop. 14: In the COVID age, can California still afford its stem cell research program? - CALmatters

California Bail Referendum-Prop 25, Stem Cell Research-Prop 14 & Affirmative Action-Prop 16 – KALW

Listen

Listening...

51:59

On this edition of Your Calls special election series, we are discussing California Propositions 25, 14 and 16.

Proposition 25 would transform how people get out of jail while awaiting trial. Proposition 14 would provide $5.5 billion in general obligation bonds for the state's stem cell research institute and make changes to the institute's governance structure and programs. Proposition 16 would restore affirmative action in public schools and government offices.

Guests:

Bob Egelko, staff writer at the San Francisco Chronicle

Danielle Venton, reporter for KQED Science

Alexander Nieves, cannabis and policy reporter for Politico California

Web Resources:

San Francisco Chronicle: California bail industry makes itself invisible opposing Prop. 25, ending cash bail

KQED: What You Need to Know About Prop 14, The Stem Cell Research Bond

Politico: California poised to reject affirmative action measure despite summer of activism

Read the original post:
California Bail Referendum-Prop 25, Stem Cell Research-Prop 14 & Affirmative Action-Prop 16 - KALW

Vanderbilt researchers make counterintuitive discoveries about immune-like characteristics of cells, chemotherapys impact on tissue growth -…

Vanderbilt University researchers have reported the counterintuitive discovery that certain chemotherapeutic agents used to treat tumors can have the opposite effect of tissue overgrowth in normal, intact mammary glands, epidermis and hair follicles. The researchers also are the first to report the discovery of an innate immune signaling pathway in fibroblaststhe spindle-shaped cells responsible for wound healing and collagen productionthat causes cells to proliferate. Such signaling pathways previously were attributed only to immune cells.

The article describing the research, DNA Damage Promotes Epithelial Hyperplasia and Fate Mis-specification via Fibroblast Inflammasome Activation, was published in the journal Developmental Cell on Oct. 13.

The findings of this work, led by postdoctoral fellow Lindsey Seldin and Professor and Chair of the Department of Cell and Developmental Biology Ian Macara, have broad implications for diseases associated with the immune system like psoriasis, as well as cancer and stem cell research.

Understanding the functionality of stem cells and the way that their behavior is regulated has been a longstanding research interest for Seldin. Normal stem cells have an amazing ability to continuously divide to maintain tissue function without forming tumors, she explained. We wanted to understand what happens to these cells in their native environment when subjected to damage, and if the response was connected to a specific tissue.

By testing perturbations to the epidermis, mammary gland and hair follicles vis--vis mechanical damage or DNA damage through chemotherapeutic agents, the researchers saw a paradoxical response: Stem cells, which otherwise would divide slowly, instead divided rapidly, promoting tissue overgrowth.

When the tissues were subjected to DNA damage, their stem cells overly proliferated, giving rise to different cells than they normally would. This was a very perplexing result, said Seldin, the papers lead author. We were determined to figure out if this was a direct response by the stem cells themselves or by inductive signals within their environment. The key clue was that stem cells isolated from the body did not behave the same way as in intact tissuean indication that the response must be provoked from signals being sent to the stem cells from other surrounding cell types.

The investigators turned their attention to fibroblasts, the predominant component of the tissue microenvironment. When fibroblasts in the epidermis were removed, the stem cell responsiveness to DNA damage was diminished, indicating that they played an important role. RNA sequencing revealed that fibroblasts can signal by way of inflammasomescomplexes within cells that help tissues respond to stress by clearing damaged cells or pathogens, which also in this case caused stem cells to divide. This is an astounding discovery, said Macara. Inflammasome signaling has previously been attributed only to immune cells, but now it seems that fibroblasts can assume an immune-like nature.

Seldin intends to replicate this work in the mammary gland to determine whether fibroblasts initiate the same innate immune response as in the epidermis, and more broadly how fibroblasts contribute to the development of cancer and other diseases associated with the immune system.

This work was supported by NCI/NIH grants R35CA132898, F32CA213794 and T32CA119925, as well as American Cancer Society grant PF-18-007-01-CCG.

Here is the original post:
Vanderbilt researchers make counterintuitive discoveries about immune-like characteristics of cells, chemotherapys impact on tissue growth -...

Biomedical Engineering Team Contributes to High-impact Study on Metabolism – University of Arkansas Newswire

Photo Submitted

An international team of researchers has published a study showing how the control of stem cell metabolism is critical to maintaining hair follicles. The study appeared in the high-impact journal Cell Metabolism.

University of Arkansas researchers included Kyle Quinn, associate professor of biomedical engineering, and Olivia Kolenc, a graduate student in Quinn's lab. The project was led by Sara Wickstrm, associate professor at the University of Helsinki, and included researchers from the research groups of Professor Sabine Eming at the University of Cologne and Martin Denzel at the Max Planck Institute for Biology of Ageing in Germany.

The team studied how the metabolism of stem cells in hair follicles is critical to the growth and long-term maintenance of hair. The follicles are unique in mammals because unlike most organs or tissues, they naturally regenerate and cycle through phases of rest, growth and degeneration. Those cycles are maintained by stem cells. Kolenc used advanced non-invasive skin imaging to monitor hair follicle metabolism in live mice.

Kolenc's work showed how the metabolism of stem cells changes as the follicle transitions to a growth phase, which provided a critical foundation to the study's larger goal of discovering the cell signaling pathways associated with the metabolic control of stem cell fate and hair follicle cycles.

The study provides insight into how our organs are maintained by stem cells and how aging can result in conditions such as hair loss. Kolenc said hair follicle stem cells aren't like some stem cells, which can transform into a wide variety of different cell types. Instead, she said, they can transform to match the surrounding area in the skin tissue.

"Hair follicle stem cells are able to differentiate into a subset of what's in their surrounding area," she said. "They can't just create any other cell, but they can contribute to regeneration and increasing the number of cells within the skin tissue."

Kolenc said hair follicle stem cells are unique among the cells in our skin because they can contribute to repair and regeneration of the skin.

"There are few populations of stem cells known to exist within the skin, so this is really a big target to help skin wound healing," she said.

Kolenc said the opportunity to contribute to such a large-scale project was special.

"It's a bit humbling," she said. "I contributed a small part to a large project that was conducted over many years. It's a cool feeling to see something like that with my name on it."

"Olivia played an important role in this study by monitoring hair follicle stem cells within their natural environment in live skin," Quinn said. "The insights she gained during this work will be very helpful as she continues studying how our metabolic imaging techniques can be applied to aging and wound healing research."

Read more from the original source:
Biomedical Engineering Team Contributes to High-impact Study on Metabolism - University of Arkansas Newswire

Letters: Yes on Prop. 14 | Walnut Creek mayor | Pleasanton mayor | Dismissing DUIs | Disrespecting Feinstein – East Bay Times

Submit your letter to the editor via this form. Read more Letters to the Editor.

Re. More Funds sought for stem-cell research, Oct. 11 :

California will lose a great deal if we do not approve Proposition 14, to renew the California stem cell program.

Five billion is a lot, no question.

But consider the astonishing cost of chronic disease, roughly $3 trillion dollars annually, according to the CDC. Diabetes alone cost America $249 billion last year 50 times the cost of the stem cell program and that is just one year!

My bout with cancer would have cost me $990,000 had I not had excellent insurance. We need to cure disease, not endlessly endure it.

More important than cash, of course, is the fight to save lives. My wife died of pancreatic cancer one of the diseases the California Institute for Regenerative Medicine is trying to cure.

Do you (or does someone you love) have one or more chronic diseases? If so (and roughly 50% of Americans do) do you want to cut off Californias research for a cure?

Don ReedFremont

I have known Kurtis Reese and his family for almost 15 years. Kurtis is intelligent, honest and a dedicated family man.

Kurtis has chosen to run for a position on the Walnut Creek City Council not because he has political aspirations, but rather to make a difference in our city, to give a much needed fresh perspective and to confront the systemic bias in our city.

Now more than ever our citys decision-makers need to include members with different experiences and perspectives. Kurtis brings a unique viewpoint that the other candidates cant. Kurtis listens and learns and is respectful of all viewpoints.

Kurtis is the leader and the change we need in Walnut Creek and that is why I am voting for him for Walnut Creek City Council.

Jenny CrepeauWalnut Creek

Other mayoral candidates may claim to be against rampant growth but the voting record against slow and smart growth speaks for itself.

Over the past 8 years as a council member or vice mayor of Pleasanton, Karla Brown has been waiting on the planning of the East Side until accurate regional housing numbers come forward. This is the most prudent and thoughtful approach. Approving a large-scale development of million-dollar-plus homes is not a realistic solution for creating state-mandated affordable housing in Pleasanton.

Karlas record on slow and smart growth planning is a testament to her commitment to preserving our quality of life. In short, Karla is the best candidate to protect our town from sprawl.

Find out the facts, follow the campaign funding and ignore the spin. Karla has demonstrated that she has a proven record of voting for slow and smart growth. She is the real deal.

Brian PullenPleasanton

I am addressing the appalling statements attributed to San Mateo County Supervisor Dave Canepa (ICE arrests in Los Angeles, Bay Area anger local officials, Oct. 9). A Guatemalan man was arrested in Canepas district and slated for deportation. He had been arrested for numerous drunk driving convictions. Canepa questioned whether his transgressions were dangerous to the public. Canepa stated, Last I heard, a DUI was a misdemeanor in California. This gentleman was not a hardened criminal but yet faces deportation now for traffic offenses. Thats just plain wrong and not the America I want to live in.

Apparently, Canepa has never had someone he loved or knew killed or injured by a drunken driver. Otherwsie, I would assume he would never say something so dismissive and insensitive.

The America I want to live in is one where numerous drunken driving charges are not thought of as traffic offenses but taken seriously as a danger to the public.

Anne WilsonMartinez

Re. Feinstein a concern ahead of court fight, Oct. 11:

I dont know with whom I am more upset the New York Times or the East Bay Times.

This isnt news, it is character assassination. I can believe this article was in the ultra-liberal NYT as another news article based on anonymous sources, who supposedly out of respect would not give their names right. By placing this article on your front page, the East Bay Times has elevated its content past opinion to news; shame on you!

Sen. Feinstein has been an honorable representative from the Bay Area for decades and when she refuses to sink to the knife fight tactics of the modern Democratic Party, you say shes too old and want to cast her away.

What irony: Feinstein is senile but Biden is capable of being president. Novel approach. Try putting forth convincing arguments. The Senate is a deliberative body, not an mixed martial arts arena.

Lorraine HumesSan Pablo

Read the original post:
Letters: Yes on Prop. 14 | Walnut Creek mayor | Pleasanton mayor | Dismissing DUIs | Disrespecting Feinstein - East Bay Times

Should California invest $5.5 billion more into promising stem cell research? – The Mercury News

1. Should California invest $5.5 billion more into promising stem cell research?  The Mercury News
2. Prop. 14 Asks Voters To OK $5.5 Billion In Bonds For Additional Stem Cell Research  KPBS
3. Editorial: California can't afford unneeded Prop 14 stem cell bond  Desert Sun
4. What California's 2004 stem cell ballot proposition has meant for University of Southern California  Mirage News
5. Danette Mitchell: Where I stand on the state propositions  Vacaville Reporter
6. View Full Coverage on Google News

Original post:
Should California invest $5.5 billion more into promising stem cell research? - The Mercury News

Comprehensive Analysis on Stem Cell Therapy Market based on types and application – AlgosOnline

The ' Stem Cell Therapy market' study Added by Market Study Report, LLC, provides an in-depth analysis pertaining to potential drivers fueling this industry. The study also encompasses valuable insights about profitability prospects, market size, growth dynamics, and revenue estimation of the business vertical. The study further draws attention to the competitive backdrop of renowned market contenders including their product offerings and business strategies.

The Stem Cell Therapy market research report offers significant information related to the key growth drivers, challenges & limitations, and various opportunities that will define the business scenario in the upcoming years.

Request a sample Report of Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2422751?utm_source=Algosonline.com&utm_medium=AN

According to the research analysis, the Stem Cell Therapy market is estimated to generate commendable returns and showcase a y-o-y growth rate of XX% over the period of 2020-20205.

The advent of COVID-19 pandemic has compelled various businesses to re-establish their respective profit trajectory for the forthcoming years. The study offers a comprehensive assessment of the impact of coronavirus outbreak on the growth of Stem Cell Therapy market.

The document also analyzes the several segmentations and their impact on the growth of this market.

Major highlights from the Stem Cell Therapy market report:

Ask for Discount on Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2422751?utm_source=Algosonline.com&utm_medium=AN

Stem Cell Therapy Market segments covered in the research report:

Regional segmentation: North America, Europe, Asia-Pacific, South America, Middle East and Africa

Product types: Autologous and Allogeneic

Applications spectrum: Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases and Others

Competitive outlook: Osiris Therapeutics, Molmed, JCR Pharmaceutical, NuVasive, Anterogen, Chiesi Pharmaceuticals, Medi-post, Pharmicell and Takeda (TiGenix

The key questions answered in the report:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Related Reports:

1. Global Transglutaminase Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Read More: https://www.marketstudyreport.com/reports/global-transglutaminase-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Oral Spray Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Read More: https://www.marketstudyreport.com/reports/global-oral-spray-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Related Report : https://www.marketwatch.com/press-release/contactless-payment-market-share-current-and-future-industry-trends-2020-2026-2020-10-12?tesla=y

Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: [emailprotected]

More here:
Comprehensive Analysis on Stem Cell Therapy Market based on types and application - AlgosOnline

How changing the stem cell response to inflammation may reverse periodontal disease – Bite magazine

Photo: Dmitrii Shironosov 123rf

US scientists have discovered that a specific type of molecule may stimulate stem cells to regenerate, reversing the inflammation caused by periodontal disease.

The current treatment for periodontal disease involves opening the infected gum flaps and adding bone grafts to strengthen the teeth.

But in research published inFrontiers in Immunology, scientists from the Forsyth Institute in Massachusetts have discovered that a specific type of molecule may stimulate stem cells to regenerate, reversing the inflammation caused by periodontal disease.

This finding could lead to the development of new therapeutics to treat a variety of systemic diseases that are characterised by inflammation in the body.

For the study, the team removed stem cells from previously extracted wisdom teeth and placed the stem cells onto petri dishes. They then created a simulated inflammatory periodontal disease environment in the petri dishes. Next, they added two specific types of synthetic molecules called Maresin-1 and Resolvin-E1, both specialised pro-resolving lipid mediators from omega-3 fatty acids.

The scientists found that Mar1 and RvE1 stimulated the stem cells to regenerate even under the inflammatory conditions.

Both Maresin-1 and Resolvin-1 reprogrammed the cellular phenotype of the human stem cells, showing that even in response to inflammation, it is possible to boost capacity of the stem cells so they can become regenerative, Dr Alpdogan Kantarci said.

This finding is important because it allows scientists to identify the specific protein pathways involved in inflammation. Those same protein pathways are consistent across many systemic diseases, including periodontal disease, diabetes, heart disease, dementia, and obesity.

Now that we understand how these molecules stimulate the differentiation of stem cells in different tissues and reverse inflammation at a critical point in time, the mechanism we identified could one day be used for building complex organs, Dr Kantarci said.

There is exciting potential for reprogramming stem cells to focus on building tissues.

Read the original:
How changing the stem cell response to inflammation may reverse periodontal disease - Bite magazine

Marcus Neuroscience Institute names Khalid A. Hanafy, M.D., Ph.D., Medical Director of Neurocritical Care and Research – Baptist Health South Florida

October 13th, 2020 Baptist Health South Florida

Boca Raton, FL October 13, 2020 Khalid A. Hanafy, M.D., Ph.D., has joined Marcus Neuroscience Institute at Boca Raton Regional Hospital, part of Baptist Health, as medical director of neurocritical care and director of research. He specializes in the care of subarachnoid hemorrhage patients and the study of neuroinflammation. He also serves as associate professor of neurology at Florida Atlantic University Charles E. Schmidt College of Medicine in Boca Raton. He is board certified in neurology and neurocritical care.

Dr. Hanafy joined Marcus Neuroscience Institute from Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Mass., where he served as the director of the neurological intensive care unit and was an assistant professor of neurology at Harvard Medical School.

We are pleased to welcome Dr. Hanafy to Marcus Neuroscience Institute, said Frank D. Vrionis, M.D., MPH, Ph.D., Institute director and chief of neurosurgery. His clinical skills, research acumen and leadership in the field of neurology will greatly benefit our team and our patients.

As the Institutes director of research, Dr. Hanafy is principal investigator of cutting-edge studies that seek to bring the most advanced, personalized treatments to subarachnoid hemorrhage patients and improve their survival rates and health outcomes. His groundbreaking work in neuroinflammation has been funded by the National Institutes of Health, American Heart Association, American Academy of Neurology, and Massachusetts Institute of Technology. Marcus Neuroscience Institute is at the forefront of stem cell therapeutics, and Dr. Hanafy and Dr. Vrionis have already initiated clinical trials using stem cells in critically ill COVID patients. Together, they will expand research and clinical trials using stem cells for the treatment of other neurological conditions, such as stroke and brain tumors.

Dr. Hanafy has authored more than 40 articles, book chapters and invited editorials in peer-reviewed scientific publications and serves on the editorial boards of scholarly journals in his field. He is a member of several professional societies, including the American Academy of Neurology, Society for Neuroscience Research, Society of Critical Care Medicine, and Neurocritical Care Society.

Dr. Hanafy earned his medical degree and doctorate degree in molecular biology at the University of Texas Medical Scientist Training Program at Houston, a dual degree program of the University of Texas McGovern Medical School and MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. He did his thesis graduate work under Dr. Ferid Murad, the 1998 Nobel laureate. He returned to these Houston facilities to complete a neurology residency following an internal medicine internship at the University of Texas Southwestern at Parkland Memorial Hospital in Dallas. He concluded his medical training with a two-year fellowship in neurological critical care at Columbia University Medical Center in New York City.

About the Marcus Neuroscience Institute The Marcus Neuroscience Institute at Boca Raton Regional Hospital is an innovative nexus for neurologic and neurosurgical care. The 57,000-square-foot facility houses a 20-bed Neuro Intensive Care and Step-Down Unit, four dedicated operating rooms including one equipped with intraoperative MRI and two with intraoperative CT capability and a biplane angiography suite, a crucial component in the diagnosis and care of neurological conditions. The Institute has a staff of five neurosurgeons and nine neurologists who represent some of the most respected clinicians in their fields and is affiliated with Florida Atlantic Universitys Charles E. Schmidt College of Medicine.

About Boca Raton Regional Hospital Boca Raton Regional Hospital is part of Baptist Health South Florida, the largest healthcare organization in the region, with 11 hospitals, nearly 23,000 employees, more than 4,000 physicians and more than 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to our faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the Worlds Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on Facebook, Instagram, Twitter and LinkedIn.

# # #

More here:
Marcus Neuroscience Institute names Khalid A. Hanafy, M.D., Ph.D., Medical Director of Neurocritical Care and Research - Baptist Health South Florida